一致Ｂ：2022年第一季度报告（英文）.PDF

《一致Ｂ：2022年第一季度报告（英文）.PDF》由会员分享，可在线阅读，更多相关《一致Ｂ：2022年第一季度报告（英文）.PDF（14页珍藏版）》请在淘文阁 - 分享文档赚钱的网站上搜索。

1、1 Stock Code: 000028/200028 Notice No.: 2022-23 Short Form of the Stock: Sinopharm Accord /Accord B China National Accord Medicines Corporation Ltd. The First Quarterly Report for 2022 The Company and whole members of the BOD guarantee that the information disclosed is true, accurate and complete, a

2、nd there are no any fictitious records, misleading statements or important omissions. Important content reminder: 1. Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National Accord Medicines Corporation Ltd. (hereinafter referred to as the Company

3、) hereby confirm that there are no any fictitious statements, misleading statements, or important omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents. 2. Principal of the Company, Person in Cha

4、rge of Accounting Works and Person in Charge of Accounting Organ (Accounting Officer) hereby confirm that the Financial Report of the First Quarterly Report is authentic, accurate and complete. 3. Whether the First Quarterly Report has been audited or not Yes No I. Main financial data (i) Main accou

5、nting data and financial indexes Whether it has retroactive adjustment or re-statement on previous accounting data or not Yes No Current Period Same period of last year Changes of this period over same period of last year Operating income (RMB) 17,150,856,946.54 16,049,966,325.75 6.86% Net profit at

6、tributable to shareholders of the listed company (RMB) 252,361,872.69 328,800,560.24 -23.25% Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses (RMB) 242,244,636.06 321,593,612.98 -24.67% Net cash flow arising from operating activities (RMB)

7、-217,452,223.38 -306,748,999.24 29.11% Basic earnings per share (RMB/Share) 0.59 0.77 -23.38% Diluted earnings per share (RMB/Share) 0.59 0.77 -23.38% Weighted average ROE 1.68% 2.33% 0.65 percentage points 2 down End of this period End of last period Changes of this period-end over same period-end

8、of last year Total assets (RMB) 44,844,103,338.63 42,783,682,431.81 4.82% Owners equity attributable to shareholders of listed company (RMB) 15,177,183,542.81 14,924,938,052.50 1.69% Explanation on the business performance and financial status: The Company achieved operation income of 17,151 million

9、 yuan for the first quarter of 2022, a year-on-year increase of 6.86%; operation profit was 375 million yuan, 20.42% down from a year earlier; the net profit attributable to shareholder of listed company was 252 million yuan, decrease of 23.25% on a year-on-year basis, the basic EPS decreased by 23.

10、38% correspondingly and weighted ROE decreased by 0.65 percentage points. Profit decline mainly due to the impact of COVID-19, the performance from affiliates declined and the investment earnings decreased accordingly. Meanwhile, the customer flow from retail segment drops due to the epidemic, and t

11、he new stores operated in 2021 have a large initial investment, the benefits are not yet visible with shrinking profit space. The distribution segment has an operation income of 12,171 million yuan, a year-on-year growth of 7.45%; net profit was 210 million yuan, a year-on-year increase of 10.40%. t

12、he retail segment has 5,238 million yuan from the operation income, a year-on-year increase of 5.11% and achieved a net profit of 32 million yuan, down 63.80% on a year-on-year basis. (ii) Items of non-recurring gains and losses Applicable Not applicable Unit: RMB/CNY Item Current amount Note Gains/

13、losses from the disposal of non-current asset (including the write-off that accrued for impairment of assets) 785,738.83 The gains on disposal of right-to-use asses arising from off-lease in the period Governmental subsidy calculated into current gains and losses(while closely related with the norma

14、l business of the Company, the government subsidy that accord with the provision of national policies and are continuously enjoyed in line with a certain standard quota or quantity are excluded) 15,562,891.34 Mainly the various special subsidies and tax rebates received in the Period Reversal of the

15、 account receivable depreciation reserves subject to separate impairment test 1,632,768.34 Other non-operating income and expenses other than the above 1,205,854.08 Other gains/losses items that meet the definition of non-recurring gains/losses 1,789,818.44 Less: impact on income tax 5,104,445.81 Im

16、pact on minority shareholders equity (post-tax) 5,755,388.59 Total 10,117,236.63 - Details of other gains/losses items that meet the definition of non-recurring gains/losses: Applicable Not applicable 3 There are no other gains/losses items that meet the definition of non-recurring gains/losses in t

17、he Company. Explain the items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public - Extraordinary Profit/loss Applicable Not applicable There are no

18、 items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public - Extraordinary Profit/loss (iii) Particulars about material changes in items of main acc

19、ounting statement and financial index and explanations of reasons Applicable Not applicable (1)Receivable financing: decrease of 557.8708 million yuan from beginning of the Period with a growth rate of -54.31%, mainly due to the increase in discounting of bank acceptance in the Period; (2) Construct

20、ion in progress: decrease of 15.0976 million yuan from beginning of the Period with a growth rate of -30.29%, mainly because the ERP project transfer-out after completion & acceptance; (3) Short-term borrowings: increase of 1,108.1141 million yuan from beginning of the Period with a growth rate of 5

21、7.40%, mainly due to the increase in financing with the invoice of account payable; (4) Employee benefits payable: decrease of 114.3872 million yuan from beginning of the Period with a growth rate of -33.62%, mainly because the wages and bonuses accrued in the prior year are paid in the Period; (5)

22、Other incomes: a year-on-year increase of 11.3852 million yuan with a growth rate of 83.37%, mainly because various subsidies received in the Period and the tax relief increased on a year-on-year basis; (6) Investment income: a year-on-year decrease of 67.8440 million yuan with a growth rate of -74.

23、30%, mainly because the performance from affiliates declined and the investment earnings decreased accordingly; (7) Credit impairment losses: a year-on-year increase of 8.7011 million yuan with a growth rate of 50.60%, mainly due to the increase of account receivable at period-end compared to the sa

24、me period of last year for the sales up; affected by the epidemic, medical insurance allocation was delayed, the capital operation from hospital are relatively tight which had a certain impact on the receivable collection of the Company, turnover days of the receivable increase to some extent, than

25、the bad debt provision goes up correspondingly; (8) Impairment losses: a year-on-year decrease of 1.8342 million yuan with a growth rate of -52.58%, mainly due to the decrease in provision for inventory falling price reserves on a year-on-year basis; (9) Gain on disposal of assets: a year-on-year in

26、crease of 0.7065 million yuan with a growth rate of 259.86%, mainly due to the increase in earnings on a year-on-year basis, resulting from disposal of the right-of-use assets for vacating from retail stores. (10)Non-operating income: a year-on-year decrease of 4.0821 million yuan with a growth rate

27、 of -64.08%, mainly because in the Period, the payable without payment requirements written off declined from a year earlier; (11) Non-controlling interests: a year-on-year decrease of 18.3534 million yuan with a growth rate of -30.20%, mainly because the net profit attributable to owners of parent

28、company from subsidiary-Sinopharm Holding Guoda Drugstore Co., Ltd.(hereinafter referred to as Guoda Drugstore) declined on a year-on-year basis, accordingly, the gains/losses of minority attributable to the strategic investor of the Group-Walgreens Boots Alliance(Hong Kong)Investments Limited (here

29、inafter referred to as WBA) decreased on a year-on-year basis; (12) Total comprehensive income attributable to non-controlling interests: a year-on-year decrease of 18.3534 million yuan with a growth rate of -30.20%, mainly because the net profit attributable to owners of parent company from subsidi

30、ary-Guoda Drugstore declined on a year-on-year basis, accordingly, the gains/losses of minority attributable to the strategic investor of the Group- WBA decreased on a year-on-year basis; (13) Receipts of taxes and surcharges refunds: a year-on-year decrease of 4.7192 million yuan with a growth rate

31、 of -84.00%, mainly 4 due to the year-on-year decline in enterprise income tax refunds received in the Period; (14) Other cash receipts relating to operating activities: a year-on-year decrease of 64.1937 million yuan with a growth rate of -30.61%, mainly because the reserve funds for epidemic-speci

32、fic, deposits and security deposit received in the Period declined from a year earlier; (15) Cash receipts from returns of investments: a year-on-year decrease of 2.9974 million yuan with a growth rate of -100.00%, mainly because in same period of last year, received the withdrawal payment from part

33、 of the projects of Sinopharm Zhongjin Medical Industry Fund, and there was no such matter occurred in the Period; (16) Cash received from investment income: a year-on-year decrease of 3.5996 million yuan with a growth rate of -100.00%, mainly because in same period of last year, received dividend p

34、ayment from projects of Sinopharm Zhongjin Medical Industry Fund, and there was no such matter occurred in the Period; (17) Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets: a year-on-year decrease of 0.2423 million yuan with a growth rate of -74.08%, mai

35、nly because the cash received in the Period from fixed assets disposal decreased from a year earlier; (18) Total cash inflows from investing activities: a year-on-year decrease of 6.8393 million yuan with a growth rate of -98.78%, mainly because in same period of last year, received dividend payment

36、 and withdrawal payment from projects of Sinopharm Zhongjin Medical Industry Fund, and there were no such matters occurred in the Period; (19) Cash payments for investments: a year-on-year decrease of 8.7574 million yuan with a growth rate of -32.34%, mainly because the payment for rental transfer f

37、ees in the Period declined from a year earlier, paid by subsidiary - Guoda Drugstore; (20) Net cash payments for acquisition of subsidiaries and other business units: a year-on-year decrease of 73.1595 million yuan with a growth rate of -100.00%, mainly because in same period of last year, subsidiar

38、y Guoda Drugstore paid for the acquisition of a subsidiary, and there was no such matter occurred in the Period; (21) Total cash outflows from investing activities: a year-on-year decrease of 67.8542 million yuan with a growth rate of -41.83%, mainly because in same period of last year, subsidiary G

39、uoda Drugstore paid for the acquisition of a subsidiary, and there was no such matter occurred in the Period; (22) Net cash flows from investing activities: a year-on-year increase of 61.0148 million yuan with a growth rate of 39.29%, mainly because in same period of last year, subsidiary Guoda Drug

40、store paid for the acquisition of a subsidiary, and there was no such matter occurred in the Period; (23) Cash proceeds from investments by others: a year-on-year decrease of 4.98 million yuan with a growth rate of -84.69%, mainly due to the year-on-year decrease in investment received from minority

41、 during the Period; (24) Other cash receipts relating to financing activities: a year-on-year decrease of 192.0255 million yuan with a growth rate of -64.56%, mainly because in the Period, the recovery of factoring business and repayment difference declined on a year-on-year basis; (25) Cash repayme

42、nts for debts: a year-on-year increase of 94.2452 million yuan with a growth rate of 53.17%, mainly due to the increase in repayment of loans due in the Period; (26) Total cash outflows from financing activities: a year-on-year increase of 161.1150 million yuan with a growth rate of 33.41%, mainly b

43、ecause repayment of loans from financial institutions and the rents paid for increasing retail stores in the Period increased on a year-on-year basis; (27) Net cash flows from financing activities: a year-on-year decrease of 276.5162 million yuan with a growth rate of -71.17%, mainly because in the

44、Period, the recovery of factoring business and repayment difference declined on a year-on-year basis, the rents paid for increasing retail stores in the Period increased on a year-on-year basis; (28) Effect of foreign exchange rate changes on cash and cash equivalents: a year-on-year increase of 1,9

45、89.89 yuan with a growth rate of 81.53%, mainly due to the change of exchange rates; (29) Net increase of cash and cash equivalents :a year-on-year decrease of 126.2026 million yuan with a growth rate of -171.70%, mainly because in the Period, the recovery of factoring business and repayment differe

46、nce declined on a year-on-year basis, the rents paid for increasing retail stores in the Period increased on a year-on-year basis. 5 II. Shareholders (i) Total number of common shareholders and preference shareholders with voting rights recovered and top ten shareholders Unit: Share Total number of

47、common shareholders at the end of report period 44,112 Total preference shareholders with voting rights recovered at end of reporting period (if applicable) 0 Top ten shareholders Shareholders name Nature of shareholder Proportion of shares held Amount of shares held Amount of lock-up shares held In

48、formation of shares pledged, tagged or frozen State of share Amount Sinopharm Group Co., Ltd. State-owned Corporation 56.06% 239,999,991 5,505,770 FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND Foreign Corporation 2.52% 10,802,495 Hong Kong Securities Clearing Company Ltd.

49、 Foreign Corporation 2.28% 9,751,340 China National Pharmaceutical Foreign Trade Corp. State-owned Corporation 1.24% 5,323,043 National Social Security Fund 413 Portfolio Domestic non state-owned Corporation 1.07% 4,590,032 BBH BOS S/A FIDELITY FD - CHINA FOCUS FD Foreign Corporation 0.78% 3,358,761

50、 Fidelity Investment Management Foreign Corporation 0.54% 2,301,737 6 (Hong Kong) Limited - Clients fund ICBC-Guolian Andesheng Small Selected Securities Investment Fund Domestic non state-owned Corporation 0.38% 1,632,000 CPIC Fund -China Pacific Life Insurance Co., Ltd. - with-profit insurance- CP